In April 2023, after a PET/CT with the SSTR agonist [64Cu]Cu-DOTATATE showing a severe progression of the hepatic involvement by tumor (February 2023), a repeated liver biopsy revealed upstaging of tumor grading to G3 (Ki67 30%), prompting the resumption of short-course chemotherapy. Here, MKI67 is linked to neoplasm.